ArticleMolecular cancer research : MCR2021

Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.

Manman Deng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.